Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company LAM Therapeutics
DescriptionKinase inhibitor
Molecular Target
Mechanism of ActionKinase inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationB cell lymphoma
Indication DetailsTreat relapsed or refractory non-Hodgkin B-cell lymphoma
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today